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New Guidelines of Clostridium Difficile
Infection (CDI)
Kashif Hussain, Specialist, Pharmacy Services

The Infectious Diseases Society of America (IDSA) and the Society for
Healthcare Epidemiology of America (SHEA) have released updated
guidelines for Clostridium difficile Infections (CDI). A major change in the
recommendations is the initial CDI treatment. For the first time in almost 3
decades, metronidazole is no longer recommended as first-line therapy in adults.
Instead, oral vancomycin (125 mg, 4 times a day) or fidaxomicin (200 mg twice
daily) are recommended for 10 days in both non-severe and severe CDI. The
change in treatment recommendation was made based on evidence to support that
use of vancomycin or fidaxomicin provide patients with the highest likelihood
of sustained symptom resolution one month after treatment. In patients with
non-severe cases of CDI, metronidazole is still recommended when patients are
unable to obtain or be treated with vancomycin or fidaxomicin.
In patients with severe, complicated CDI with shock, hypotension, ileus, or
megacolon, vancomycin 500 mg 4 times a day is recommended with parenteral
metronidazole. Patients with ileus can be administered vancomycin via enema.
Metronidazole is not recommended for recurrent CDI infections.The guidelines
do not make a recommendation regarding the role of probiotics.Pharmacists can
play an important role in ensuring the optimal treatment approach for patients
with CDI, particularly when it appears that a patient may be being treated for
CDI according to outdated guidelines.
Reference:
l
McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for
Clostridium difficile infection in adults and children: 2017 update by the Infectious
Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America
(SHEA). Clin Infect Disease. 2018

Drug Incompatibility and Medication Error
Mohd Amir, Specialist, Pharmacy Services

Intravenous medication may interact with other causing physicochemical
incompatibilities. As a result of it, drug efficacy may be reduced or risk of
adverse effect may increase, thus causing a medication error. Medication
incompatibility may cause 20 % of all medication errors and 89% of
administration errors. Drug incompatibility can be visible ( color change,
clouding and precipitation) or can be invisible ( pH changes, complex reaction).
Drug incompatibility can be caused at the time preparation and administration. In
term of preparation, incompatibility is caused, if a drug is reconstituted or diluted
with a non-compatible solution or drugs as admixtures. While administration, it
may be caused as due to Y-site administration or mixing two drugs in a syringes.
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In this three methods; admixture, Y-site administration and syringe preparation; drugs are allowed time to interact
with each other and hence may cause incompatibility. Incompatibility does not exist if drugs are given by central line
catheter or peripherally inserted central catheter. Furthermore, incompatibility does not occur, if drugs are given via two
different arms peripheral lines. With respect to blood, it’s not advisable to administer drug with it from same line.
Reference:
l
Medication Error and drug Incompatibility [Internet]. ELCAM SAFETY; Retrieved from: http://www.infusesafety.com/medicationerrors---drug-incompatibility

Botulinum Toxin Type –A: An Option to Treat Carpal Tunnel
Syndrome (CTS)
Areeba Nayab, Trainee Pharmacist

Carpal tunnel syndrome (CTS) affects approximately 1–3% of the population. It is a clinical condition in which the
median nerve of the wrist is entrapped and undergoes irritation, often attributed to compression. CTS is associated with
a significant increase in interstitial pressure, and a resulting compromise of blood flow. When that pressure persists, the
symptoms related to CTS appear. Symptoms include paresthesias in the thumb, index, middle and radial half of the ring
finger, and pain in the hand and wrist that can radiate to the forearm.
Botulinum toxin (BTX) has been successfully used in the treatment of spasmodic torticollis, limb dystonia, and
spasticity. Botulinum toxins A (Botox, by Allergan, Irvine, CA) and B (Myobloc, by Solstice Neurosciences, San
Francisco, CA) have recently been used for the management of a variety of painful states (e.g., primary headaches,
back pain, myofascial pain, painful dystonia The mechanism for their analgesic effect may be related to acetylcholine
inhibition and/or a blocking action of the release of neuropeptides and glutamate from primary afferents. Botulinum
toxin type A (BTX-A) paralyzes skeletal muscles by inhibiting the exocytosis of acetylcholine at the cholinergic nerve
endings of motor nerves, and is also reportedly effective at alleviating various pain conditions, including neuropathic
pain and headache, independent of its effect on muscle contraction.
The mechanism underlying the antinociceptive action of BTX-A in neuropathic pain conditions has been hypothesized
to be related to BTX-A’s noted ability to inhibit the release of several noncholinergic neurotransmitters (including
substance P, calcitonin gene-related peptide, and glutamate) associated with neurogenic inflammation, and possibly
peripheral sensitization. As nerve injury induces the release of such agents, peripheral BTX-A treatment might alleviate
some of the symptoms of neuropathic pain.
References:
l
Breuer B, Sperber K, Wallenstein S, Kiprovski K, Calapa A, Snow B, Pappagallo M. Clinically significant placebo analgesic response in
a pilot trial of botulinum B in patients with hand pain and carpal tunnel syndrome. Pain medicine. 2006 Jan 1;7(1):16-24.
l

Jeynes LC, Gauci CA. Evidence for the use of botulinum toxin in the chronic pain setting—a review of the literature. Pain Practice. 2008
Jul 1;8(4):269-76.

l

Yoon SH, Merrill RL, Choi JH, Kim ST. Use of botulinum toxin type A injection for neuropathic pain after trigeminal nerve injury. Pain
Medicine. 2010 Mar 31;11(4):630-2.

Hydrocortisone Plus Fludrocortisone for Adults with Septic Shock –
The Latest Approach
Nimra Iqbal Surti, Pharmacist

Septic shock is a dysregulated host body response to an infection concomitantly with circulatory, cellular and metabolic
abnormalities. Hydrocortisone and Fludrocortisones are corticosteroids that respond as cardiovascular function
enhancers and anti-inflammatory agents in state of septic shock.
The multicenter, double-blind, randomized APROCCHSS (Activated Protein C and corticosteroid for Human Septic
Shock) Clinical trial comprising 1241 patients hypothesized that therapy with hydrocortisone plus fludrocortisone or with

3

Pharmacy Newsletter

drotrecogin alfa (activated) would improve the clinical outcomes of patients with septic shock through host response
modulation. The trial compared patients who received hydrocortisone plus fludrocortisone with those who did not (placebo
group). The Treatment regime of the trial comprised 50mg intravenous bolus of Hydrocortisone every 6 hrs and once daily
administration of 50-μg tablet of fludrocortisone in morning. However the rate of serious adverse events did not differ
significantly between the two groups, but hyperglycemia was more common in hydrocortisone-plus-fludrocortisone group.
Hence the APROCCHSS clinical trial concluding in favor of the proposed hypothesis clearly indicates that the
concomitant use of hydrocortisone with fludrocortisone to treat patients with septic shock using the trial treatment
regimen will result in favorable clinical outcomes in such patients.
Reference:
l
Djillali Annane et al, Hydrocortisone plus Fludrocortisone for Adults with Septic Shock, N Engl J Med 2018; 378:809-818.
Daniel De Backer, Todd Dorman; Surviving Sepsis Guidelines: A Continuous Move toward Better Care of Patients with Sepsis JAMA.
2017 Feb 28; 317(8):807-808.

l

Adverse Drug Reactions (ADR) Reporting Trend at AKUH – Year 2017
Dr Ale zehra, Clinical Pharmacist

Adverse drug reaction (ADR) are any response to a drug that is noxious, unintended and that occurs at doses normally
used for prophylaxis, diagnosis or therapy. The main purpose of ADR reporting and monitoring is to provide an indirect
measure of the quality of pharmaceutical care through identification of preventable ADRs and anticipatory surveillance
for high-risk drugs or patients. The data will help to monitor trends and significant isolated ADRs, create a feedback
loop to practitioners, promote educational endeavors to prevent ADRs, and improve patient outcomes.
Year 2017 data shows a total number of 132 ADRs were reported (with exception of many unreported too). Following
are the details of reported ADRs: Antibiotics: In year 2017, majority of ADRs were reported from Antibiotic and
Neoplastic class of drugs. These mainly were rashes and hypersensitivity reactions. Learning outcomes are:
l

All antibiotics/neoplastic drugs must be infused slowly over period time recommended by the drug information
resources (mention on the patient labels).

l

Avoid administration of antibiotics in high concentrations where possible, decrease rate of infusion if using
maximum concentration of dilution.

l

If patient develops allergy or hypersensitivity to any antibiotic it must be documented in patient record and
updated in the Pharmacy system to avoid any further administration.

		
		
		

Adverse drug Reactions are reported in AKUH through;
Yellow Cards
http://portal.aku.edu/pharmacy/adrrf.html
Through ADR Hot line: Ext:1479

l
l
l

ADR - Year 2017
Total Number of Rx’s in 2017

1,423,257

Total ADR’s Reported

132

Therapeutic Class wise ADR Reporting Trend at AKUH | Year 2017
¡
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¡
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¡

NSAIDs

¡

Immunomodulator

¡

Anticoagulants
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Benzodiazepines

¡

Xanthine Oxidase Inhibitor

¡

General anesthetic
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Iron preparation
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Antiviral

¡

Miscellaneous
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Medication Reconciliation: Step to Enter Patient Home Medication
Entry
Hafsah Ashfaq, Clinical Pharmacist

STEP 01

Message will appear

Medication Reconciliation is an important step for patient
safety; please update patient’s Past Medication History
before proceeding with the order

STEP 02

1.
2.
•
•
•

Upon selection of first 2 options, system will not further prompt the user unless Dr wants to update the list later
Upon selection of last option, system will allow the Dr to proceed with the order but as soon as 24 hrs clock is completed, it will restrict further 		
order entry unless the list is updated.
Last option should be used if the history:
Is there but still incomplete,
Temporarily not available (attendant / last prescription etc. not present)
Order entry is more critical to stabilize the patient in 1st 24 hrs of admission

STEP 03

•
Medication name can be selected in 2 ways:
		
o
Formulary (as available in AKUH)
		
o
Choose from predefine list of drugs
•
Non Formulary (other brands/products)
		o
Free Text Entry
•
Proper Dose, frequency and route of administration as described by patient is to be entered

STEP 04

Dr will take decision on each medication as mentioned:
•
Continue (during admission)
•
Hold till Discharge
•
Discontinue
Drugs to be continued must be entered in the system as a routine order.

Provide us your Valuable Feedback!

To keep the Pharmacy Newsletter of Aga Khan University Hospital (AKUH) updated we would like to take your valuable feedback. We are grateful
to you for sparing few minutes of your precious time to complete form by below online link or form can be emailed to you as well. Just drop us an
email with subject Newsletter Feedback. Email us at:drug.information@aku.edu
Thank you in advance for your feedback!
Link:
https://goo.gl/forms/Ghh1Nc2KY2jEkiUL2
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